Skip to content
Meta-analysis Open access

Positive and Negative Symptoms Changes in Schizophrenia Patients on Antipsychotic Treatment: a Systematic Review and Dose–Response Meta-analysis

Aug 2026 · Schizophrenia bulletin · Vol 52 · 0 citations · 36 references
Medicine

TL;DR

The effects of antipsychotics on negative symptoms are smaller than those on positive symptoms, at least in studies of mostly acutely exacerbated patients, and the dose–response curves for both types of symptoms are relatively parallel.

Abstract

Abstract Background and Hypothesis Positive and negative symptoms are core features of schizophrenia and key indicators of antipsychotic efficacy. We aimed to explore the relationship between antipsychotic doses and changes in positive/negative symptoms. Study Design We reviewed the Cochrane Schizophrenia Group register (updated on July-26-2024) and prior systematic reviews to identify fixed-dose randomized controlled trials that assessed the monotherapy effects of 21 antipsychotic drugs in acute schizophrenia. The primary outcome measure was the average change in positive and negative symptoms from the studies’ baseline to endpoint, calculated using standard mean differences as the effect size metric. Dose–response relationships were analyzed using random-effects meta-analyses with restricted cubic splines. Study Results Finally, a total of 165 studies were identified. 112 studies with 385 dose arms (37 096 participants) reported positive or negative symptoms and were evaluated in meta-analyses. Most antipsychotics showed parallel dose–response curves for positive and negative symptoms, with a smaller magnitude of effect on negative symptoms—except a few drugs, in particular partial dopamine agonists which had at least equal effect sizes for positive and negative symptoms. In most cases both curves declined until reaching an inflection point, then plateaued or efficacy decreased. Conclusions The effects of antipsychotics on negative symptoms are smaller than those on positive symptoms, at least in studies of mostly acutely exacerbated patients. Nevertheless, the dose–response curves for both types of symptoms are relatively parallel. This information can assist clinicians in dosing antipsychotics and has implications for the understanding of the antipsychotic mechanism.

Read PDF

Similar papers

Review Open access Sep 2026

Comparative efficacy of antipsychotics for reducing aggression in schizophrenia: systematic review and network meta-analysis.

BACKGROUND Antipsychotics are used to manage hostility and aggressive behaviour in schizophrenia, but their comparative efficacy remains unclear. AIMS To compare the efficacy of antipsychotics for reducing hostility and aggressive behaviour in schizophrenia. METHOD We searched PubMed, PsycINFO, ClinicalTrials.gov,...

Jelle Lamsma, E. Ostinelli, Andrea Cipriani et al. · 0 citations
Open access Sep 2026

Clinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms

Background Impaired clinical insight in schizophrenia is associated with poor treatment adherence and outcomes. Previous research on the influence of symptoms, cognition, and antipsychotic exposure has been inconclusive and restricted to multi-episode samples. We examined time-specific associations between overall psyc...

L. Stabell, Erik Johnsen, R. Kroken et al. · 0 citations
Review Open access Sep 2026

Effect of dopamine partial agonist antipsychotics on suicide risk in persons with schizophrenia and schizoaffective disorders: A systematic review and meta-analysis

Background and hypothesis: Clozapine is the only antipsychotic with protective effects against suicide in schizophrenia (SCZ). Newer dopamine partial agonist (DPA) antipsychotics have better tolerability and modulate serotonin, dopamine, and N-methyl-d-aspartate neurotransmission pathways implicated in suicide. We aim...

J. Jin, Charlotte J. Winkler, H. Blunt et al. · 0 citations
Open access Aug 2026

Relapse trajectories and antipsychotic discontinuation in schizophrenia from individual participant data of five trials from the Yale Open Data Access database: a meta-analysis.

It is found that rapid relapse was not over-represented among those who discontinued treatment, which is not the pattern expected if rapid relapse following paliperidone discontinuation were commonly a pharmacological discontinuation effect.

Krisya Louie, S. Jauhar, J. Rubio et al. · 1 citation
Open access Sep 2026

580. Clinical treatment pathways of antipsychotics in patients with schizophrenia spectrum disorder: a retrospective longitudinal observational study

This analysis of antipsychotic prescribing for first-episode SSD from 2014-2019 found quetiapine, olanzapine, aripiprazole, risperidone, and amisulpride were the most common initial agents, and the shift toward quetiapine aligns with international trends.

Q. Bo, T. Li, Y. Wang et al. · 0 citations
Open access Sep 2026

Patterns, predictors and outcomes of the joint trajectories of positive and negative symptoms in patients with early psychosis: 12-year follow-up of the randomized controlled trial on extended early intervention.

BACKGROUND Positive and negative symptoms are considered core features of psychotic disorders. However, no study has identified joint trajectories of positive and negative symptoms in early psychosis with long-term follow-up. METHOD We conducted 12-year follow-up of a randomized-controlled trial on extended early int...

Chris Chit Sze Fung, Ryan Sai-Ting Chu, Natalie Wing Tung Chu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.